Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances
F Wu, T Jin - Aaps Pharmscitech, 2008 - Springer
While the concept of using polymer-based sustained-release delivery systems to maintain
therapeutic concentration of protein drugs for extended periods of time has been well …
therapeutic concentration of protein drugs for extended periods of time has been well …
Diagnosis and treatment of hypopituitarism: an update
MO Van Aken, SWJ Lamberts - Pituitary, 2005 - Springer
Diagnosis and treatment of patients with hypopituitarism needs careful clinical evaluation
and individual optimization. Symptoms of hypopituitarism are variable, often insidious in …
and individual optimization. Symptoms of hypopituitarism are variable, often insidious in …
Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies
F Jordan, A Naylor, CA Kelly, SM Howdle… - Journal of Controlled …, 2010 - Elsevier
Novel sustained release formulations of hGH prepared by supercritical fluid processing of
PLGA/PLA (the CriticalMix™ process) were produced in the form of microparticles for …
PLGA/PLA (the CriticalMix™ process) were produced in the form of microparticles for …
Growth hormone receptor modulators
V Birzniece, A Sata, KKY Ho - Reviews in endocrine and metabolic …, 2009 - Springer
Growth hormone (GH) regulates somatic growth, substrate metabolism and body
composition. Its actions are elaborated through the GH receptor (GHR). GHR signalling …
composition. Its actions are elaborated through the GH receptor (GHR). GHR signalling …
Local antitumor effects of intratumoral delivery of rlL-2 loaded sustained-release dextran/PLGA–PLA core/shell microspheres
In this study, we formulated a rIL-2 loaded sustained-release dextran/PLGA–PLA core/shell
microsphere, mimicking the paracrine mechanisms of cytokine action, to investigate its local …
microsphere, mimicking the paracrine mechanisms of cytokine action, to investigate its local …
Research Progress on Injectable Microspheres as New Strategies for the Treatment of Osteoarthritis Through Promotion of Cartilage Repair
J Lin, S Jia, F Cao, J Huang, J Chen… - Advanced Functional …, 2024 - Wiley Online Library
Osteoarthritis (OA) is a degenerative disease caused by a variety of factors with joint pain as
the main symptom, including fibrosis, chapping, ulcers, and loss of cartilage. Traditional …
the main symptom, including fibrosis, chapping, ulcers, and loss of cartilage. Traditional …
Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD)
F Peter, M Bidlingmaier, C Savoy, HJ Ji… - The Journal of …, 2012 - academic.oup.com
Background: GH treatment currently requires daily sc injections, resulting in suboptimal
compliance. A GH regimen with fewer injections may offer patients and caregivers a less …
compliance. A GH regimen with fewer injections may offer patients and caregivers a less …
Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide
JF Langenheim, WY Chen - Journal of Endocrinology, 2009 - joe.bioscientifica.com
To prolong the circulation half-life of human prolactin (hPRL), human GH (hGH), and their
competitive antagonists, hPRL-G129R and hGH-G120R, we examined the effects of fusing a …
competitive antagonists, hPRL-G129R and hGH-G120R, we examined the effects of fusing a …
Biodegradable microspheres for parenteral delivery
VR Sinha, A Trehan - Critical Reviews™ in Therapeutic Drug …, 2005 - dl.begellhouse.com
Nowadays, emphasis is being laid to development of controlled release dosage forms.
Interest in this technology has increased steadily over the past few years. Although oral …
Interest in this technology has increased steadily over the past few years. Although oral …
Comparative Pharmacokinetics and Pharmacodynamics of a New Sustained-Release Growth Hormone (GH), LB03002, Versus Daily GH in Adults with GH …
Context: LB03002 is a novel sustained-release GH preparation administered once weekly.
Objective: Our objective was to examine the pharmacokinetics, pharmacodynamics, and …
Objective: Our objective was to examine the pharmacokinetics, pharmacodynamics, and …